Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-01-2 Purità > 99.0% Febuxostat Fabbrika Intermedja
Ruifu Chemical Supply Febuxostat Intermedji Relatati:
Febuxostat CAS 144060-53-7
Ethyl 2-Chloroacetoacetate CAS 609-15-4
4-Hydroxythiobenzamide CAS 25984-63-8
Ethyl 2-(3-Cyano-4-Hydroxyphenyl)-4-Methyl-1,3-Thiazole-5-Carboxylate CAS 161798-02-3
Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylate CAS 160844-75-7
Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-01-2
Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-03-4
Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5
Isem Kimiku | Etil 2-(3-Formil-4-Idrossifenil)-4-Methylthiazole-5-Carboxylate |
Sinonimi | 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylic Acid Ethyl Ester;Febuxostat Intermedju |
Numru CAS | 161798-01-2 |
Numru tal-KAT | RF-PI1111 |
Status tal-istokk | Fil-Ħażna, Skala ta' Produzzjoni Sa Tunnellati |
Formula Molekulari | C14H13NO4S |
Piż Molekulari | 291.32 |
Punt tat-tidwib | 113.0 sa 117.0 ℃ |
Brand | Ruifu Kimika |
Oġġett | Speċifikazzjonijiet |
Dehra | Trab Isfar għal Isfar ċar |
Solubilità | Kampjun ta '1.0g jista' jiġi maħlul fi 30ml dichloromethane u dimethyl sulfoxide |
Identifikazzjoni UV | Assorbiment massimu f'tul ta 'mewġ ta' 260nm±3nm u 321nm±3nm |
Umdità (KF) | ≤0.50% |
Residwu mat-Tqabbid | ≤0.50% |
Impurità Unika mhux magħrufa | ≤0.50% |
Impuritajiet Totali | ≤1.0% |
Purità / Metodu ta 'Analiżi | ≥99.0% (Ikkalkulat fuq il-bażi anidruża) |
Standard tat-Test | Standard tal-Intrapriża |
Użu | Intermedju ta' Febuxostat (CAS: 144060-53-7) |
Pakkett: Flixkun, borża tal-fojl tal-aluminju, 25kg/Drum tal-Kartun, jew skont il-ħtieġa tal-klijent.
Kundizzjoni tal-Ħżin:Aħżen f'kontenituri ssiġillati f'post frisk u niexef;Ipproteġi mid-dawl u l-umdità
Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate (CAS: 161798-01-2) huwa intermedju ta' Febuxostat (CAS: 144060-53-7).Febuxostat huwa inibitur ta 'xanthine oxidase ta' ġenerazzjoni ġdida żviluppat minn Tejin Co. (Ġappun,) użat klinikament għal trattament fit-tul ta 'hyperuicemia (gotta,) inibitur selettiv mhux purine ġdid u effettiv ħafna ta' xanthine oxidase.Mhux rakkomandat għal pazjenti tal-gotta mingħajr iperuriċemija.